Supercharged immune cells take on childhood cancers
NCT ID NCT04715191
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This early-phase trial tests a new immunotherapy called CARE T cells in children and young adults with solid tumors that have returned or not responded to standard treatment. The cells are taken from the patient, genetically modified to recognize a protein (GPC3) found on many solid tumors, and given extra signals (IL15 and IL21) to help them survive and fight longer. The main goals are to find a safe dose and see if the cells can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CARE T cells (genetically modified immune cells with GPC3-CAR, IL15, and IL21)
- What this could lead to
- If it works, this could point toward a new treatment option for children with hard-to-treat solid tumors like liver cancer or rhabdomyosarcoma.
- What could go wrong
- This is a very early (Phase 1) trial with only 24 participants, so it is too soon to know if the cells are effective. There are also risks of serious side effects, including cytokine release syndrome and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- A new test could reveal how radiation affects the liver
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can engineered immune cells tackle childhood sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?